Cardiovascular risk associated with interactions among polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-8

  Bentley, John P ^a   Asselbergs, Folkert W ^b,f   Coffey, Christopher S ^c   Hebert, Patricia R ^d   Moore, Jason H ^e   Hillege, Hans L ^f   van Gilst, Wiek H ^f  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF IOWA   (United States)

^d FLORIDA ATLANTIC UNIVERSITY   (United States)

^e DARTMOUTH MEDICAL SCHOOL   (United States)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ANGIOTENSIN RECEPTOR; ASPARTIC ACID; BRADYKININ B2 RECEPTOR; CYSTEINE; DIPEPTIDYL CARBOXYPEPTIDASE; FIBRINOLYTIC FACTOR; GLYCINE; ISOLEUCINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THREONINE; TISSUE PLASMINOGEN ACTIVATOR; BRADYKININ;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; EXON; FEMALE; FIBRINOLYSIS; GENE INTERACTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; POPULATION RESEARCH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; AGED; CAUCASIAN; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; BRADYKININ; CARDIOVASCULAR DISEASES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; POLYMORPHISM, GENETIC; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 77958580697     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012757     Document Type: Article

References (36)

1. Saksela O, Rifkin DB (1988) Cell-associated plasminogen activation: Regulation and physiological functions. Annu Rev Cell Biol 4: 93-126.
2. Thögersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, et al. (1998) High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98: 2241-2247.
3. Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, et al. (2000) Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 20: 2019-2023.
4. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, et al. (1993) Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 87: 1969-1973.
5. Vaughan DE, Rouleau JL, Ridker PM, Arnold JM, Menapace FJ, et al. (1997) Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation 96: 442-447.
6. Brown NJ, Agirbasli M, Vaughan DE (1999) Comparative effect of angiotensinconverting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 34: 285-290.
7. Brown NJ, Abbas A, Byrne D, Schoenhard JA, Vaughan DE (2002) Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women. Circulation 105: 304-309.
8. Minai K, Matsumoto T, Horie H, Ohira N, Takashima H, et al. (2001) Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: Effects of angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 37: 1565-1570.
9. Asselbergs FW, Williams SM, Hebert PR, Coffey CS, Hillege HL, et al. (2006) The gender-specific role of polymorphisms from the fibrinolytic, reninangiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels. Thromb Haemost 96: 471-477.
10. Moore JH, Smolkin ME, Lamb JM, Brown NJ, Vaughan DE (2002) The relationship between plasma t-PA and PAI-1 levels is dependent on epistatic effects of the ACE I/D and PAI-1 4G/5G polymorphisms. Clin Genet 62: 53-59.
11. Asselbergs FW, Williams SM, Hebert PR, Coffey CS, Hillege HL, et al. (2007) Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels. Genomics 89: 362-369.
12. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, et al. (1992) Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359: 641-644.
13. Ruiz J, Blanché H, Cohen N, Velho G, Cambien F, et al. (1994) Insertion/ deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 91: 3662-3665.
14. Eriksson P, Kallin B, van't Hooft FM, Ba°venholm P, Hamsten A (1995) Allelespecific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 92: 1851-1855.
15. Margaglione M, Cappucci G, Colaizzo D, Giuliani N, Vecchione G, et al. (1998) The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Vasc Biol 18: 152-156.
16. Pinto-Sietsma SJ, Janssen WM, Hillege HL, Navis G, De Zeeuw D, et al. (2000) Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. J Am Soc Nephrol 11: 1882-1888.
17. Geluk CA, Post WJ, Hillege HL, Tio RA, Tijssen JG, et al. (2008) C-reactive protein and angiographic characteristics of stable and unstable coronary artery disease: Data from the prospective PREVEND cohort. Atherosclerosis 196: 372-382.
18. Borggreve SE, Hillege HL, Wolffenbuttel BH, de Jong PE, Zuurman MW, et al. (2006) An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to high high-density lipoprotein cholesterol: A population-based study. J Clin Endocrinol Metab 91: 3382-3388.
19. Skinner CJ, Holt D, Smith TMF (1989) Analysis of complex surveys. Chichester: John Wiley and Sons.
20. Verhave JC, Hillege HL, Burgerhof JG, Janssen WM, Gansevoort RT, et al. (2004) Sodium intake affects urinary albumin excretion especially in overweight subjects. J Intern Med 256: 324-330.
21. Mahmoodi BK, Gansevoort RT, Veeger NJ, Matthews AG, Navis G, et al. (2009) Microalbuminuria and risk of venous thromboembolism. JAMA 301: 1790-1797.
22. Asselbergs FW, Williams SM, Hebert PR, Coffey CS, Hillege HL, et al. (2007) Gender-specific correlations of plasminogen inhibitor-1 and tissue plasminogen activator levels with cardiovascular disease-related traits. J Thromb Haemost 5: 313-320.
23. Kim DK, Kim JW, Kim S, Gwon HC, Ryu JC, et al. (1997) Polymorphism of angiotensin converting enzyme gene is associated with circulating levels of plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 17: 3242-3247.
24. Pankow JS, Arnett DK, Borecki IB, Hunt SC, Eckfeldt JH, et al. (2000) Lack of association between the angiotensin-converting enzyme insertion/deletion polymorphism and plasminogen activator inhibitor-1 antigen levels in the National Heart, Lung, and Blood Institute Family Heart Study. Blood Coagul Fibrinolysis 11: 551-558.
25. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, et al. (1990) An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86: 1343-1346.
26. Coffey CS, Hebert PR, Ritchie MD, Krumholz HM, Gaziano JM, et al. (2004) An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene interactions on risk of myocardial infarction: The importance of model validation. BMC Bioinformatics 5: 49-58.
27. González Ordóñez AJ, Fernández Carreira JM, Medina Rodríguez JM, Martín Sánchez L, Alvarez Díaz R, et al. (2000) Risk of venous thromboembolism associated with the insertion/deletion polymorphism in the angiotensinconverting enzyme gene. Blood Coagul Fibrinolysis 11: 485-490.
28. Wells PS, Rodger MA, Forgie MA, Langlois NJ, Armstrong L, et al. (2003) The ACE D/D genotype is protective against the development of idiopathic deep vein thrombosis and pulmonary embolism. Thromb Haemost 90: 829-834.
29. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S (1991) Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 11: 183-190.
30. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, et al. (1993) The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 268: 10739-10745.
31. Brown NJ, Gainer JV, Murphey LJ, Vaughan DE (2000) Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenaseindependent pathway. Circulation 102: 2190-2196.
32. Labinjoh C, Newby DE, Pellegrini MP, Johnston NR, Boon NA, et al. (2001) Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition. J Am Coll Cardiol 38: 1402-1408.
33. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, et al. (2001) Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 69: 138-147.
34. Hahn LW, Ritchie MD, Moore JH (2003) Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 19: 376-382.
35. Gerds TA, Schumacher M (2007) Efron-type measures of prediction error for survival analysis. Biometrics 63: 1283-1287.
36. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr., Vasan RS (2008) Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 27: 157-172.